Search is Powered by Google
Cancer / Oncology News

Cross-species comparison reveals shared features between tumorigenesis and organogenesis

Main Category: Cancer / Oncology
Article Date: 20 Mar 2004 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

A new study, published in the March 15th issue of Genes & Development, provides critical new insight into the shared mechanisms of normal organ development and solid tumor formation.

By studying the cerebellum (the structure in the brain largely responsible for coordinating motor activities) Drs. Alvin Kho, Isaac Kohane, David Rowitch, and colleagues at The Children's Hospital and Dana-Farber Cancer Institute in Boston have developed a novel method for comparing the genetic changes associated with normal development in mice with that of the most common malignancy of the pediatric nervous system, medulloblastoma.

'With information derived from the Human Genome Project we now have the ability to easily compare and identify meaningful patterns of gene expression between species such as mouse and human,' said Kho, a postdoctoral fellow and the paper's lead author. Such cross-species comparison provides a powerful new tool for understanding the genetic changes associated with human tumor development.

In a developing organ, the pattern of gene expression changes as the individual cells commit to their own specialized functions. By analyzing the changing patterns of expression of more than 2000 genes in the developing cerebellum in mice and comparing these to genes expressed in human medulloblastomas, the investigators were able to characterize the malignant cells from a developmental perspective.

The researchers found that different types of medulloblastomas share many common features with cerebellar cells at the very earliest stages of their development, further emphasizing that malignant cells have disrupted developmental programs.

'These findings have exploited our ability to analyze thousands of independently segregating genetic markers to confirm the classic proposals by investigators such as Lobstein and Cohnheim in the 19th century that tumorigenesis recapitulates aspects of development,' Rowitch said.

Kohane and Rowitch's research is important for two reasons. Firstly, this novel method provides a generalizable framework within which gene expression in development and tumorigenesis can be studied. By this means, the role of a particular gene in tumor progression can be better understood. And secondly, since this analysis is readily applicable to other tumor types it can be developed as a useful tool for both tumor diagnosis and prognosis.

Indeed, the investigators show that similar findings are obtained when a human squamous cell lung cancer is compared with the developing rodent lung. 'Much work remains to be done to determine whether the 'developmental perspective' can lead to clinically meaningful insights such as advances in diagnosis or our understanding of tumor behavior,' Kohane said. 'This study provides a foundation to ask these questions and facilitate translation of a large basic science knowledge base into the clinical sphere.'

Contact: Heather Cosel
coselpie@cshl.org
Cold Spring Harbor Laboratory




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

customize your homepage

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...